Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics

Lindsey M. Hoffman, Mariko DeWire, Scott Ryall, Pawel Buczkowicz, James Leach, Lili Miles, Arun Ramani, Michael Brudno, Shiva Senthil Kumar, Rachid Drissi, Phillip Dexheimer, Ralph Salloum, Lionel Chow, Trent Hummel, Charles Stevenson, Q. Richard Lu, Blaise Jones, David Witte, Bruce Aronow, Cynthia E. HawkinsMaryam Fouladi

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction, immunohistochemistry, and fluorescent in-situ hybridization.

RESULTS: Median age at diagnosis was 6.1 years (range: 2.9-23.3 years). Median overall survival was 13.2 months (range: 11.2-32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4) or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA (n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B (n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR (n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.

CONCLUSION: Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)1
Number of pages1
JournalActa neuropathologica communications
Volume4
DOIs
StatePublished - Jan 4 2016

Fingerprint

Glioma
Biopsy
Mutation
Therapeutics
Neoplasms
Exome
Astrocytoma
Fluorescence In Situ Hybridization
Brain Neoplasms
Autopsy
Immunohistochemistry
Pediatrics
Neoplasm Metastasis
Polymerase Chain Reaction
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma : implications for diagnostic biopsy and targeted therapeutics. / Hoffman, Lindsey M.; DeWire, Mariko; Ryall, Scott; Buczkowicz, Pawel; Leach, James; Miles, Lili; Ramani, Arun; Brudno, Michael; Kumar, Shiva Senthil; Drissi, Rachid; Dexheimer, Phillip; Salloum, Ralph; Chow, Lionel; Hummel, Trent; Stevenson, Charles; Lu, Q. Richard; Jones, Blaise; Witte, David; Aronow, Bruce; Hawkins, Cynthia E.; Fouladi, Maryam.

In: Acta neuropathologica communications, Vol. 4, 04.01.2016, p. 1.

Research output: Contribution to journalArticle

Hoffman, LM, DeWire, M, Ryall, S, Buczkowicz, P, Leach, J, Miles, L, Ramani, A, Brudno, M, Kumar, SS, Drissi, R, Dexheimer, P, Salloum, R, Chow, L, Hummel, T, Stevenson, C, Lu, QR, Jones, B, Witte, D, Aronow, B, Hawkins, CE & Fouladi, M 2016, 'Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics', Acta neuropathologica communications, vol. 4, pp. 1. https://doi.org/10.1186/s40478-015-0269-0
Hoffman, Lindsey M. ; DeWire, Mariko ; Ryall, Scott ; Buczkowicz, Pawel ; Leach, James ; Miles, Lili ; Ramani, Arun ; Brudno, Michael ; Kumar, Shiva Senthil ; Drissi, Rachid ; Dexheimer, Phillip ; Salloum, Ralph ; Chow, Lionel ; Hummel, Trent ; Stevenson, Charles ; Lu, Q. Richard ; Jones, Blaise ; Witte, David ; Aronow, Bruce ; Hawkins, Cynthia E. ; Fouladi, Maryam. / Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma : implications for diagnostic biopsy and targeted therapeutics. In: Acta neuropathologica communications. 2016 ; Vol. 4. pp. 1.
@article{54c514f2f0394220b975354927798672,
title = "Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics",
abstract = "INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction, immunohistochemistry, and fluorescent in-situ hybridization.RESULTS: Median age at diagnosis was 6.1 years (range: 2.9-23.3 years). Median overall survival was 13.2 months (range: 11.2-32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4) or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA (n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B (n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR (n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.CONCLUSION: Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy.",
author = "Hoffman, {Lindsey M.} and Mariko DeWire and Scott Ryall and Pawel Buczkowicz and James Leach and Lili Miles and Arun Ramani and Michael Brudno and Kumar, {Shiva Senthil} and Rachid Drissi and Phillip Dexheimer and Ralph Salloum and Lionel Chow and Trent Hummel and Charles Stevenson and Lu, {Q. Richard} and Blaise Jones and David Witte and Bruce Aronow and Hawkins, {Cynthia E.} and Maryam Fouladi",
year = "2016",
month = "1",
day = "4",
doi = "10.1186/s40478-015-0269-0",
language = "English (US)",
volume = "4",
pages = "1",
journal = "Acta neuropathologica communications",
issn = "2051-5960",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma

T2 - implications for diagnostic biopsy and targeted therapeutics

AU - Hoffman, Lindsey M.

AU - DeWire, Mariko

AU - Ryall, Scott

AU - Buczkowicz, Pawel

AU - Leach, James

AU - Miles, Lili

AU - Ramani, Arun

AU - Brudno, Michael

AU - Kumar, Shiva Senthil

AU - Drissi, Rachid

AU - Dexheimer, Phillip

AU - Salloum, Ralph

AU - Chow, Lionel

AU - Hummel, Trent

AU - Stevenson, Charles

AU - Lu, Q. Richard

AU - Jones, Blaise

AU - Witte, David

AU - Aronow, Bruce

AU - Hawkins, Cynthia E.

AU - Fouladi, Maryam

PY - 2016/1/4

Y1 - 2016/1/4

N2 - INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction, immunohistochemistry, and fluorescent in-situ hybridization.RESULTS: Median age at diagnosis was 6.1 years (range: 2.9-23.3 years). Median overall survival was 13.2 months (range: 11.2-32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4) or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA (n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B (n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR (n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.CONCLUSION: Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy.

AB - INTRODUCTION: Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction, immunohistochemistry, and fluorescent in-situ hybridization.RESULTS: Median age at diagnosis was 6.1 years (range: 2.9-23.3 years). Median overall survival was 13.2 months (range: 11.2-32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4) or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA (n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B (n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR (n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved.CONCLUSION: Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=85017046717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017046717&partnerID=8YFLogxK

U2 - 10.1186/s40478-015-0269-0

DO - 10.1186/s40478-015-0269-0

M3 - Article

C2 - 26727948

AN - SCOPUS:85017046717

VL - 4

SP - 1

JO - Acta neuropathologica communications

JF - Acta neuropathologica communications

SN - 2051-5960

ER -